Abstract
Polygenic diseases require the co-occurrence of multiple risk variants to initiate a pathology. An example is preeclampsia, a hypertensive disease of pregnancy with no known cure or therapy other than the often-preterm delivery of the neonate and placenta. Preeclampsia is challenging to predict due to symptomatic and outcome heterogeneity. Transcriptomic and genetic analysis suggests that this is a multi-syndromic and multigenic disease. Previous research applications of traditional GWAS methods to preeclampsia identified only a few alleles with marginal differences between cases and controls. We seek to identify genetic networks related to the pathophysiology of preeclampsia as potential avenues of therapeutic investigation and early genetic testing. We created a novel systems biology-based method that identifies networks of co-occurring SNPs associated with a trait or disease. The co-occurring pairs are assembled into higher-order associations using network graphs. We validated our method using simulation modelling and tested it against maternal genetic data of a previously assessed preeclampsia cohort. The genetic co-occurrence network identified SNPs in or near genes with ontological enrichment for VEGF, immunological and hormonal pathways, among others with known physiological disruption in preeclampsia. Our findings suggests that preeclampsia is caused by relatively common alleles (<5%) that accumulate in unfavorable combinations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
BJC was supported by Tier 2 Canada Research Chair in maternal fetal communication and AO was supported by a graduate scholarship from NSERC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Genotyping data was obtained from the European Genome-Phenome Archive's dataset repository. The Wellcome Trust Case Control Consortium (WTC) originally collected the data. The PE dataset (EGAD00010000854) containing maternal genomic data and the control dataset (EGAD00000000022) were collected separately, though both cohorts were from the United Kingdom.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Genotyping data was obtained from the European Genome-Phenome Archive's dataset repository. The Wellcome Trust Case Control Consortium (WTC) originally collected the data. The PE dataset (EGAD00010000854) containing maternal genomic data and the control dataset (EGAD00000000022) were collected separately, though both cohorts were from the United Kingdom.
